Kedudukan dalam Saham
#25796
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering,... Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Harga Saham
$4.80
Disegerakkan terakhir: 2026-08-20
Perubahan (1 hari)
-16.52%
Perubahan (1 tahun)
101.68%
Perdagangan Edesa Biotech, Inc. (EDSA)
Harga EDSA dengan permodalan pasaran b
Modal pasaran bagi Edesa Biotech, Inc.(EDSA)
Modal Pasaran: $46.24M
Sehingga August 2026, Edesa Biotech, Inc. mempunyai modal pasaran sebanyak $46.24M. Ini menjadikan Edesa Biotech, Inc. syarikat ke-25796th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Edesa Biotech, Inc. dari 2010 hingga 2026
EDSA berbanding dengan 5 teratas yang paling popular stocks
| Harga EDSA |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.257T
|
+11,368,556.10%
|
|
|
|
|
$4.599T
|
+9,945,110.35%
|
|
|
|
|
$4.107T
|
+8,880,944.52%
|
|
|
|
|
$3.577T
|
+7,736,196.86%
|
|
|
|
|
$2.807T
|
+6,071,079.53%
|
